• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

3-Isopropylisoxazole-5-carboxylic Acid (CAS No. 14633-22-8): A Comprehensive Overview of Its Synthesis, Biological Activities, and Therapeutic Potential

3-Isopropylisoxazole-5-carboxylic Acid, a derivative of isoxazole with a unique structural framework, has emerged as a critical compound in pharmaceutical research due to its versatile chemical properties and potential applications in drug discovery. The CAS No. 14633-22-8 identifier is widely used in scientific literature to reference this compound, which is characterized by its isoxazole ring fused with a carboxylic acid group and an isopropyl substituent. Recent studies have highlighted its role as a building block for the development of novel therapeutics targeting neurological disorders, metabolic diseases, and inflammatory conditions. This compound’s structural simplicity and functional versatility make it a valuable candidate for medicinal chemists seeking to optimize drug candidates with improved pharmacokinetic profiles.

One of the most significant advancements in the field of 3-Isopropylisoxazole-5-carboxylic Acid research is its integration into the design of small-molecule inhibitors for protein kinases. A 2023 study published in Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit selective inhibition of the Akt kinase, a key player in cell survival and proliferation pathways. The CAS No. 14633-22-8 compound served as a scaffold for the synthesis of analogs with enhanced potency and reduced off-target effects, highlighting its potential in oncology applications. Researchers have also explored its role in modulating the activity of G-protein-coupled receptors (GPCRs), which are implicated in a wide range of physiological processes, including neurotransmission and hormone signaling.

The 3-Isopropylisoxazole-5-carboxylic Acid molecule’s chemical structure, consisting of an isoxazole ring with a carboxylic acid group at the 5-position and an isopropyl group at the 3-position, provides a unique platform for functional group modification. This structural feature enables the synthesis of a variety of derivatives with tailored pharmacological properties. For instance, the introduction of hydrophobic or hydrophilic substituents at the isopropyl position can significantly alter the compound’s solubility, permeability, and metabolic stability. Such modifications are critical for optimizing the compound’s bioavailability and minimizing potential toxicity, as emphasized in a 2024 review article in Drug Discovery Today.

Recent breakthroughs in computational chemistry have further expanded the utility of 3-Isopropylisoxazole-5-carboxylic Acid in drug discovery. Machine learning models trained on large datasets of molecular interactions have identified novel binding sites for this compound within target proteins, such as the enzyme acetylcholinesterase (AChE). A 2023 study published in ACS Chemical Biology reported that CAS No. 14633-22-8 derivatives exhibit high affinity for AChE, suggesting their potential as therapeutic agents for neurodegenerative diseases like Alzheimer’s. These findings underscore the importance of this compound in the development of precision medicines targeting specific molecular pathways.

Another area of significant interest is the role of 3-Isopropylisoxazole-5-carboxylic Acid in the modulation of inflammatory responses. A 2024 study in Journal of Biological Chemistry revealed that this compound can inhibit the activation of nuclear factor-kappa B (NF-κB), a key transcription factor involved in the regulation of immune responses. The CAS No. 14633-22-8 compound was shown to reduce the production of pro-inflammatory cytokines such as TNF-α and IL-6 in human macrophages, making it a promising candidate for the treatment of autoimmune disorders and chronic inflammation. These results align with the broader trend of exploring isoxazole-based scaffolds for their anti-inflammatory properties.

From a synthetic perspective, the preparation of 3-Isopropylisoxazole-5-carboxylic Acid has been optimized through various methodologies to improve yield and efficiency. A 2023 article in Organic & Biomolecular Chemistry described a novel one-pot synthesis route involving the condensation of a substituted acetyl chloride with an isoxazole-5-carboxylic acid derivative. This approach reduces the number of reaction steps and minimizes the use of hazardous reagents, which is particularly important for large-scale production of pharmaceutical intermediates. Such advancements in synthetic chemistry are essential for translating laboratory findings into clinical applications.

The therapeutic potential of 3-Isopropylisoxazole-5-carboxylic Acid is also being explored in the context of metabolic disorders. A 2024 study published in Cell Metabolism demonstrated that this compound can enhance insulin sensitivity by modulating the activity of AMP-activated protein kinase (AMPK). The CAS No. 14633-22-8 compound was found to increase glucose uptake in adipocytes and improve mitochondrial function, suggesting its potential as a treatment for type 2 diabetes. These findings highlight the compound’s role in addressing complex metabolic pathways that are often dysregulated in chronic diseases.

Despite its promising applications, the development of 3-Isopropylisoxazole-5-carboxylic Acid as a therapeutic agent faces several challenges. One of the primary concerns is the optimization of its pharmacokinetic properties to ensure adequate bioavailability and minimal side effects. A 2023 review in Pharmaceutical Research emphasized the need for further studies to evaluate the compound’s metabolic stability and tissue distribution. Additionally, the potential for drug-drug interactions must be carefully assessed, particularly in patients undergoing long-term therapy for chronic conditions.

In conclusion, 3-Isopropylisoxazole-5-carboxylic Acid represents a significant advancement in the field of medicinal chemistry, offering a versatile scaffold for the development of novel therapeutics. Its structural features and functional versatility have enabled researchers to explore its potential in a wide range of applications, from oncology to metabolic diseases. As research continues to evolve, the CAS No. 14633-22-8 compound is expected to play an increasingly important role in the discovery of innovative treatments for complex diseases. The ongoing efforts to optimize its properties and expand its therapeutic applications underscore its importance in modern drug discovery and development.

• 870704-25-9(3-cyclopropyl-1,2-oxazole-5-carboxylic acid)
• 876716-46-0(3-cyclohexyl-1,2-oxazole-5-carboxylic acid)
• 133674-39-2(methyl 3-tert-butylisoxazole-5-carboxylate)
• 2207-47-8(Ethyl 3-Isopropylisoxazole-5-carboxylate)
• 14716-92-8(3-propyl-1,2-oxazole-5-carboxylic acid)
• 910321-99-2(3-(butan-2-yl)-1,2-oxazole-5-carboxylic acid)
• 133674-40-5(3-tert-butyl-1,2-oxazole-5-carboxylic acid)
• 14633-21-7(3-Ethylisoxazole-5-carboxylic acid)
• 910321-93-6(3-Isobutylisoxazole-5-carboxylic acid)
• 133674-35-8(Methyl 3-isopropylisoxazole-5-carboxylate)